Form 4: Eterna Therapeutics Director Peter Cicala Acquires Stock Options
SEC Form 4 Filing
Director Peter Cicala acquired stock options for 51,485 shares of Eterna Therapeutics common stock on February 7, 2025.
Summary
- Peter Cicala, a director of Eterna Therapeutics Inc., acquired stock options on February 7, 2025.
- The options grant him the right to buy 51,485 shares of Eterna Therapeutics common stock at an exercise price of $0.34 per share.
- The options vest over time, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in 24 equal monthly installments.
- The options expire on February 7, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in corporate compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of the transaction (acquisition of stock options) |
| 02/07/2025 | Grant date of the stock options |
| 02/10/2025 | Date of signature |
| 02/07/2035 | Expiration date of the stock options |
Keywords
stock options, director, ERNA, Eterna Therapeutics, beneficial ownership, Form 4, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.